These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8314411)

  • 1. Intervention with nicotinamide in pre-type 1 diabetes: the Deutsche Nikotinamid Interventionsstudie-DENIS.
    Lampeter EF
    Diabete Metab; 1993; 19(1 Pt 2):105-9. PubMed ID: 8314411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes.
    Cabrera-Rode E; Molina G; Arranz C; Vera M; González P; Suárez R; Prieto M; Padrón S; León R; Tillan J; García I; Tiberti C; Rodríguez OM; Gutiérrez A; Fernández T; Govea A; Hernández J; Chiong D; Domínguez E; Di Mario U; Díaz-Díaz O; Díaz-Horta O
    Autoimmunity; 2006 Jun; 39(4):333-40. PubMed ID: 16891222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.
    Lampeter EF; Klinghammer A; Scherbaum WA; Heinze E; Haastert B; Giani G; Kolb H
    Diabetes; 1998 Jun; 47(6):980-4. PubMed ID: 9604880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the sequential design of the Deutsche Nikotinamid Interventionsstudie--DENIS.
    Haastert B; Giani G
    Diabete Metab; 1993; 19(1 Pt 2):100-4. PubMed ID: 8314410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT).
    European Nicotinamide Diabetes Intervention Trial Group
    Diabetologia; 2003 Mar; 46(3):339-46. PubMed ID: 12687331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic and immunologic risks for development of type 1 diabetes--experiences from an intervention trial].
    Undlien DE; Joner G; Dahl-Jørgensen K; Rønningen KS; Nicol-Smith L; Torjesen PA; Søvik O
    Tidsskr Nor Laegeforen; 2000 Sep; 120(23):2799-803. PubMed ID: 11107929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Islet autoantibodies, nationality and gender: a multinational screening study in first-degree relatives of patients with Type I diabetes.
    Williams AJ; Bingley PJ; Moore WP; Gale EA;
    Diabetologia; 2002 Feb; 45(2):217-23. PubMed ID: 11935153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
    Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
    Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
    Gale EA; Bingley PJ; Emmett CL; Collier T;
    Lancet; 2004 Mar; 363(9413):925-31. PubMed ID: 15043959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young age and HLA markers enhance the risk of progression to type 1 diabetes in antibody-positive siblings of diabetic children.
    Yamamoto AM; Deschamps I; Garchon HJ; Roussely H; Moreau N; Beaurain G; Robert JJ; Bach JF
    J Autoimmun; 1998 Dec; 11(6):643-50. PubMed ID: 9878086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Giessen-Bad Oeynhausen family study: improved prediction of type I diabetes in a low incidence population of relatives using combinations of islet autoantibodies in a dual step model.
    Jaeger C; Hatziagelaki E; Stroedter A; Becker F; Scherer S; Petzoldt R; Federlin K; Bretzel RG
    Exp Clin Endocrinol Diabetes; 1999; 107(8):496-505. PubMed ID: 10612480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of beta-cell destruction in IDDM: the role of nicotinamide.
    Gale EA
    Horm Res; 1996; 45 Suppl 1():39-43. PubMed ID: 8805029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes.
    Truyen I; De Grijse J; Weets I; Kaufman L; Pipeleers L; Nanos N; Decochez K; Hilbrands R; Kaufman JM; Keymeulen B; Mathieu C; Van Gaal L; Pipeleers DG; Gorus FK;
    Clin Exp Immunol; 2007 Aug; 149(2):243-50. PubMed ID: 17521324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of antibodies to GAD-65 and IA-2ic can replace the islet-cell antibody assay to identify subjects at risk of type 1 diabetes mellitus.
    Hatziagelaki E; Jaeger C; Petzoldt R; Seissler J; Scherbaum WA; Federlin K; Bretzel RG
    Horm Metab Res; 1999 Oct; 31(10):564-9. PubMed ID: 10596966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives.
    Maclaren N; Lan M; Coutant R; Schatz D; Silverstein J; Muir A; Clare-Salzer M; She JX; Malone J; Crockett S; Schwartz S; Quattrin T; DeSilva M; Vander Vegt P; Notkins A; Krischer J
    J Autoimmun; 1999 Jun; 12(4):279-87. PubMed ID: 10330299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of diabetes-specific autoantibodies in parents of children with type 1 diabetes. DENIS study group.
    Seissler J; Atik Y; Klinghammer A; Scherbaum WA
    Horm Metab Res; 1999 Dec; 31(12):657-61. PubMed ID: 10668918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide.
    Herskowitz RD; Jackson RA; Soeldner JS; Eisenbarth GS
    J Autoimmun; 1989 Oct; 2(5):733-7. PubMed ID: 2529865
    [No Abstract]   [Full Text] [Related]  

  • 18. The natural history of pre-type 1 (insulin-dependent) diabetes mellitus in patients with autoimmune endocrine diseases.
    Betterle C; Presotto F; Magrin L; Pedini B; Moro L; Caretto A; Zanchetta R
    Diabetologia; 1994 Jan; 37(1):95-103. PubMed ID: 8150236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enterovirus antibody levels during the first two years of life in prediabetic autoantibody-positive children.
    Sadeharju K; Lönnrot M; Kimpimäki T; Savola K; Erkkilä S; Kalliokoski T; Savolainen P; Koskela P; Ilonen J; Simell O; Knip M; Hyöty H
    Diabetologia; 2001 Jul; 44(7):818-23. PubMed ID: 11508265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group.
    Komulainen J; Knip M; Lounamaa R; Vähäsalo P; Karjalainen J; Sabbah E; Akerblom HK
    Diabet Med; 1997 Jul; 14(7):532-7. PubMed ID: 9223390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.